CNBC 快讯 4月16日 17:44 RFK Jr.的多肽政策或为Hims & Hers增长提供催化，但信息不足以支撑即时交易 RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opp… FG 100 读报告 →